Distinct Mu, Delta, and Kappa opioid receptor mechanisms underlie low sociability and depressive-like behaviors during heroin abstinence

Neuropsychopharmacology

Volumn 39, Issue 11, 2014, Pages 2694-2705

  Lutz, Pierre Eric ^a,b   Ayranci, Gulebru ^a   Chu Sin Chung, Paul ^a   Matifas, Audrey ^a   Koebel, Pascale ^a   Filliol, Dominique ^a   Befort, Katia ^a   Ouagazzal, Abdel Mouttalib ^a   Kieffer, Brigitte L ^a,b  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; DIAMORPHINE; FLUOXETINE; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; NARCOTIC AGENT;

129 MOUSE; ANIMAL; C57BL MOUSE; DEPRESSION; DISEASE MODEL; DORSAL RAPHE NUCLEUS; DRUG EFFECTS; GENETICS; HEROIN DEPENDENCE; KNOCKOUT MOUSE; MALE; MEMORY DISORDER; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGY; SHORT TERM MEMORY; SOCIAL BEHAVIOR; SPATIAL MEMORY; SUBSTANCE WITHDRAWAL SYNDROME;

ANIMALS; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DEPRESSION; DISEASE MODELS, ANIMAL; DORSAL RAPHE NUCLEUS; FLUOXETINE; HEROIN; HEROIN DEPENDENCE; MALE; MEMORY DISORDERS; MEMORY, SHORT-TERM; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; NARCOTICS; RECEPTORS, OPIOID, KAPPA; RECEPTORS, OPIOID, MU; SOCIAL BEHAVIOR; SPATIAL MEMORY; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84930888521     PISSN: 0893133X     EISSN: 1740634X     Source Type: Journal    
DOI: 10.1038/npp.2014.126     Document Type: Article

References (57)

1. Andersen JM, Ripel A, Boix F, Normann PT, Morland J (2009). Increased locomotor activity induced by heroin in mice: pharmacokinetic demonstration of heroin acting as a prodrug for the mediator 6-monoacetylmorphine in vivo. J Pharmacol Exp Ther 331: 153-161.
2. Anraku T, Ikegaya Y, Matsuki N, Nishiyama N (2001). Withdrawal from chronic morphine administration causes prolonged enhancement of immobility in rat forced swimming test. Psychopharmacology 157: 217-220.
3. Aston-Jones G, Harris GC (2004). Review-Brain substrates for increased drug seeking during protracted withdrawal. Neuropharmacology 47(Suppl 1): 167-179.
4. Bakken K, Landheim AS, Vaglum P (2007). Axis I and II disorders as long-term predictors of mental distress: a six-year prospective follow-up of substance-dependent patients. BMC Psychiatry 7: 29.
5. Berger AL, Williams AM, McGinnis MM, Walker BM (2013). Affective cue-induced escalation of alcohol self-administration and increased 22-kHz ultrasonic vocalizations during alcohol withdrawal: role of kappa-opioid receptors. Neuropsychopharmacology 38: 647-654.
6. Berton O, Hahn CG, Thase ME (2012). Are we getting closer to valid translational models for major depression? Science 338: 75-79.
7. Blatchford KE, Diamond K, Westbrook RF, McNally GP (2005). Increased vulnerability to stress following opiate exposures: behavioral and autonomic correlates. Behav Neurosci 119: 1034-1041.
8. Bruchas MR, Land BB, Chavkin C (2010). The dynorphin/kappa opioid system as a modulator of stress-induced and proaddictive behaviors. Brain Res 1314: 44-55.
9. Challis C, Boulden J, Veerakumar A, Espallergues J, Vassoler FM, Pierce RC et al (2013). Raphe GABAergic neurons mediate the acquisition of avoidance after social defeat. J Neurosci 33: 13978-13988.
10. Chu Sin Chung P, Kieffer BL (2013). Delta opioid receptors in brain function and diseases. Pharmacol Ther 140: 112-120.
11. Darke S, Mills K, Teesson M, Ross J, Williamson A, Havard A (2009). Patterns of major depression and drug-related problems amongst heroin users across 36 months. Psychiatry Res 166: 7-14.
12. Del Boca C, Lutz PE, Le Merrer J, Koebel P, Kieffer BL (2012). Cholecystokinin knock-down in the basolateral amygdala has anxiolytic and antidepressant-like effects in mice. Neuroscience 218: 185-195.
13. File SE, Seth P (2003). A review of 25 years of the social interaction test. Eur J Pharmacol 463: 35-53.
14. Filliol D, Ghozland S, Chluba J, Martin M, Matthes HW, Simonin F et al (2000). Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet 25: 195-200.
15. Gerra G, Borella F, Zaimovic A, Moi G, Bussandri M, Bubici C et al (2004). Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug Alcohol Depend 75: 37-45.
16. Goeldner C, Lutz PE, Darcq E, Halter T, Clesse D, Ouagazzal AM et al (2011). Impaired emotional-like behavior and serotonergic function during protracted abstinence from chronic morphine. Biol Psychiatry 69: 236-244.
17. Goeldner C, Reiss D, Kieffer BL, Ouagazzal AM (2010). Endogenous nociceptin/orphanin-FQ in the dorsal hippocampus facilitates despair-related behavior. Hippocampus 20: 911-916.
18. Grasing K, Ghosh S (1998). Selegiline prevents long-term changes in dopamine efflux and stress immobility during the second and third weeks of abstinence following opiate withdrawal. Neuropharmacology 37: 1007-1017.
19. Grella CE, Karno MP, Warda US, Niv N, Moore AA (2009). Gender and comorbidity among individuals with opioid use disorders in the NESARC study. Addict Behav 34: 498-504.
20. Gururajan A, Taylor DA, Malone DT (2010). Current pharmacological models of social withdrawal in rats: relevance to schizophrenia. Behav Pharmacol 21: 690-709.
21. Hack SP, Bagley EE, Chieng BC, Christie MJ (2005). Induction of delta-opioid receptor function in the midbrain after chronic morphine treatment. J Neurosci 25: 3192-3198.
22. Harris GC, Aston-Jones G (1993). Beta-adrenergic antagonists attenuate somatic and aversive signs of opiate withdrawal. Neuropsychopharmacology 9: 303-311.
23. Harris GC, Aston-Jones G (2001). Augmented accumbal serotonin levels decrease the preference for a morphine associated environment during withdrawal. Neuropsychopharmacology 24: 75-85.
24. Hodgson SR, Hofford RS, Wellman PJ, Eitan S (2009). Different affective response to opioid withdrawal in adolescent and adult mice. Life Sci 84: 52-60.
25. Hyman SE, Malenka RC, Nestler EJ (2006). Neural mechanisms of addiction: the role of reward-related learning and memory. Annu Rev Neurosci 29: 565-598.
26. Jia W, Liu R, Shi J, Wu B, Dang W, Du Y et al (2013). Differential regulation of MAPK phosphorylation in the dorsal hippocampus in response to prolonged morphine withdrawal-induced depressive-like symptoms in mice. PLoS One 8: e66111.
27. Kallupi M, Wee S, Edwards S, Whitfield TW Jr., Oleata CS, Luu G et al (2013). Kappa opioid receptor-mediated dysregulation of gamma-aminobutyric acidergic transmission in the central amygdala in cocaine addiction. Biol Psychiatry 74: 520-528.
28. Kest B, Palmese CA, Hopkins E, Adler M, Juni A, Mogil JS (2002). Naloxone-precipitated withdrawal jumping in 11 inbred mouse strains: evidence for common genetic mechanisms in acute and chronic morphine physical dependence. Neuroscience 115: 463-469.
29. Klein G, Juni A, Waxman AR, Arout CA, Inturrisi CE, Kest B (2008). A survey of acute and chronic heroin dependence in ten inbred mouse strains: evidence of genetic correlation with morphine dependence. Pharmacol Biochem Behav 90: 447-452.
30. Knoll AT, Carlezon WA Jr. (2010). Dynorphin, stress, and depression. Brain Res 1314: 56-73.
31. Koob GF, Volkow ND (2010). Neurocircuitry of addiction. Neuropsychopharmacology 35: 217-238.
32. Lutz PE, Kieffer BL (2013a). Opioid receptors: distinct roles in mood disorders. Trends Neurosci 36: 195-206.
33. Lutz PE, Pradhan AA, Goeldner C, Kieffer BL (2011). Sequential and opposing alterations of 5-HT(1A) receptor function during withdrawal from chronic morphine. Eur Neuropsychopharmacol 21: 835-840.
34. Lutz PE, Reiss D, Ouagazzal AM, Kieffer BL (2013b). A history of chronic morphine exposure during adolescence increases despair-like behaviour and strain-dependently promotes sociability in abstinent adult mice. Behav Brain Res 243: 44-52.
35. Ma MX, Chen YM, He J, Zeng T, Wang JH (2007). Effects of morphine and its withdrawal on Y-maze spatial recognition memory in mice. Neuroscience 147: 1059-1065.
36. Mandillo S, Tucci V, Holter SM, Meziane H, Banchaabouchi MA, Kallnik M et al (2008). Reliability, robustness, and reproducibility in mouse behavioral phenotyping: a cross-laboratory study. Physiol Genomics 34: 243-255.
37. Meyer-Lindenberg A, Tost H (2012). Neural mechanisms of social risk for psychiatric disorders. Nat Neurosci 15: 663-668.
38. Nunes EV, Sullivan MA, Levin FR (2004). Treatment of depression in patients with opiate dependence. Biol Psychiatry 56: 793-802.
39. Ornstein TJ, Iddon JL, Baldacchino AM, Sahakian BJ, London M, Everitt BJ et al (2000). Profiles of cognitive dysfunction in chronic amphetamine and heroin abusers. Neuropsychopharmacology 23: 113-126.
40. Pickens CL, Airavaara M, Theberge F, Fanous S, Hope BT, Shaham Y (2011). Neurobiology of the incubation of drug craving. Trends Neurosci 34: 411-420.
41. Pothion S, Bizot JC, Trovero F, Belzung C (2004). Strain differences in sucrose preference and in the consequences of unpredictable chronic mild stress. Behav Brain Res 155: 135-146.
42. Ragozzino ME, Gold PE (1995). Glucose injections into the medial septum reverse the effects of intraseptal morphine infusions on hippocampal acetylcholine output and memory. Neuroscience 68: 981-988.
43. Rapeli P, Kivisaari R, Autti T, Kahkonen S, Puuskari V, Jokela O et al (2006). Cognitive function during early abstinence from opioid dependence: a comparison to age, gender, and verbal intelligence matched controls. BMC Psychiatry 6: 9.
44. Sakoori K, Murphy NP (2005). Maintenance of conditioned place preferences and aversion in C57BL6 mice: effects of repeated and drug state testing. Behav Brain Res 160: 34-43.
45. Schlosburg JE, Whitfield TW Jr., Park PE, Crawford EF, George O, Vendruscolo LF et al (2013). Long-term antagonism of kappa opioid receptors prevents escalation of and increased motivation for heroin intake. J Neurosci 33: 19384-19392.
46. Simonin F, Schmitt M, Laulin JP, Laboureyras E, Jhamandas JH, MacTavish D et al (2006). RF9, a potent and selective neuropeptide FF receptor antagonist, prevents opioid-induced tolerance associated with hyperalgesia. Proc Natl Acad Sci USA 103: 466-471.
47. Smith JS, Schindler AG, Martinelli E, Gustin RM, Bruchas MR, Chavkin C (2012). Stress-induced activation of the dynorphin/kappa-opioid receptor system in the amygdala potentiates nicotine conditioned place preference. J Neurosci 32: 1488-1495.
48. Solecki W, Ziolkowska B, Krowka T, Gieryk A, Filip M, Przewlocki R (2009). Alterations of prodynorphin gene expression in the rat mesocorticolimbic system during heroin self-administration. Brain Res 1255: 113-121.
49. Tao R, Auerbach SB (2002). GABAergic and glutamatergic afferents in the dorsal raphe nucleus mediate morphine-induced increases in serotonin efflux in the rat central nervous system. J Pharmacol Exp Ther 303: 704-710.
50. Tao R, Auerbach SB (2005). mu-Opioids disinhibit and kappaopioids inhibit serotonin efflux in the dorsal raphe nucleus. Brain Res 1049: 70-79.
51. Trezza V, Baarendse PJ, Vanderschuren LJ (2010). The pleasures of play: pharmacological insights into social reward mechanisms. Trends Pharmacol Sci 31: 463-469.
52. Ukai M, Watanabe Y, Kameyama T (2000). Effects of endomorphins- 1 and -2, endogenous mu-opioid receptor agonists, on spontaneous alternation performance in mice. Eur J Pharmacol 395: 211-215.
53. Wall PM, Blanchard RJ, Yang M, Blanchard DC (2003). Infralimbic D2 receptor influences on anxiety-like behavior and active memory/attention in CD-1 mice. Prog Neuropsychopharmacol Biol Psychiatry 27: 395-410.
54. Weibel R, Reiss D, Karchewski L, Gardon O, Matifas A, Filliol D et al (2013). Mu opioid receptors on primary afferent nav1.8 neurons contribute to opiate-induced analgesia: insight from conditional knockout mice. PLoS One 8: e74706.
55. Wikler A, Pescor FT (1970). Persistence of 'relapse-tendencies' of rats previously made physically dependent on morphine. Psychopharmacologia 16: 375-384.
56. Zhang D, Zhou X, Wang X, Xiang X, Chen H, Hao W (2007). Morphine withdrawal decreases responding reinforced by sucrose self-administration in progressive ratio. Addict Biol 12: 152-157.
57. Zhao ZQ, Gao YJ, Sun YG, Zhao CS, Gereau RWt, Chen ZF (2007). Central serotonergic neurons are differentially required for opioid analgesia but not for morphine tolerance or morphine reward. Proc Natl Acad Sci USA 104: 14519-14524.